National Vision Holdings ROE 2015-2018 | EYE
Current and historical return on equity (ROE) values for National Vision Holdings (EYE) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. National Vision Holdings ROE for the three months ending September 30, 2018 was 7.18%.
| National Vision Holdings ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2018-09-30 | $0.07B | $0.76B | 10.21% |
| 2018-06-30 | $0.07B | $0.73B | 11.71% |
| 2018-03-31 | $0.06B | $0.71B | 13.53% |
| 2017-12-31 | $0.05B | $0.66B | 20.55% |
| 2017-09-30 | $0.02B | $0.26B | 28.24% |
| 2017-06-30 | $0.02B | $0.00B | inf% |
| 2017-03-31 | $0.02B | $0.00B | 20.73% |
| 2016-12-31 | $0.00B | $0.00B | 3.11% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $2.624B | $1.375B |
| National Vision Holdings, Inc. is involved in optical retail primarily in the United States. The company offer product and services for eye care needs through retail stores and consumer websites. Its brand portfolio consists of America's Best Contacts & Eyeglasses, Eyeglass World, Vision Centers inside select Walmart stores and Vista Optical locations inside Fred Meyer stores and on select military bases. National Vision Holdings, Inc. is headquartered in Duluth, Georgia. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $132.164B | 26.13 |
| Medtronic (MDT) | Ireland | $123.923B | 18.53 |
| Stryker (SYK) | United States | $69.625B | 25.56 |
| Boston Scientific (BSX) | United States | $55.366B | 27.03 |
| Baxter (BAX) | United States | $39.075B | 24.08 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.222B | 16.18 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.659B | 0.00 |
| ResMed (RMD) | United States | $14.394B | 27.30 |
| Canopy Growth (CGC) | Canada | $11.042B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.100B | 51.79 |
| Aurora Cannabis (ACB) | Canada | $7.040B | 50.36 |
| Hill-Rom Holdings (HRC) | United States | $6.974B | 21.57 |
| Perrigo (PRGO) | Ireland | $6.650B | 10.09 |
| Insulet (PODD) | United States | $5.226B | 0.00 |
| ICU Medical (ICUI) | United States | $5.190B | 28.91 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.539B | 0.00 |
| Haemonetics (HAE) | United States | $4.489B | 39.82 |
| Agios Pharmaceuticals (AGIO) | United States | $3.462B | 0.00 |
| Hutchison China MediTech (HCM) | China | $3.417B | 0.00 |
| Neogen (NEOG) | United States | $3.281B | 50.39 |
| NuVasive (NUVA) | United States | $3.013B | 28.03 |
| Quidel (QDEL) | United States | $2.581B | 23.28 |
| Aphria (APHA) | $2.402B | 106.67 | |
| NxStage Medical (NXTM) | United States | $1.954B | 0.00 |
| AtriCure (ATRC) | United States | $1.279B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.231B | 17.70 |
| VAREX IMAGING (VREX) | United States | $1.198B | 23.45 |
| Cardiovascular Systems (CSII) | United States | $1.170B | 840.00 |
| MacroGenics (MGNX) | United States | $0.923B | 0.00 |
| Cerus (CERS) | United States | $0.878B | 0.00 |
| PetIQ (PETQ) | United States | $0.837B | 21.68 |
| Surmodics (SRDX) | United States | $0.766B | 111.39 |
| Evolus (EOLS) | United States | $0.747B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.719B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.713B | 22.07 |
| Meridian Bioscience (VIVO) | United States | $0.704B | 20.98 |
| OraSure Technologies (OSUR) | United States | $0.703B | 31.03 |
| Omeros (OMER) | United States | $0.688B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.625B | 20.05 |
| Quanterix (QTRX) | United States | $0.505B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.492B | 24.18 |
| Owens & Minor (OMI) | United States | $0.479B | 5.42 |
| TG Therapeutics (TGTX) | United States | $0.395B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.368B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.334B | 21.65 |
| BioLife Solutions (BLFS) | United States | $0.299B | 404.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.293B | 0.00 |
| Bovie Medical (APYX) | United States | $0.279B | 0.00 |
| Vapotherm (VAPO) | United States | $0.276B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.262B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.242B | 0.00 |
| Zynex (ZYXI) | United States | $0.165B | 15.97 |
| Surface Oncology (SURF) | United States | $0.150B | 0.00 |
| Fonar (FONR) | United States | $0.143B | 7.65 |
| Chembio Diagnostics (CEMI) | United States | $0.119B | 0.00 |
| Chimerix (CMRX) | United States | $0.101B | 0.00 |
| United-Guardian (UG) | United States | $0.091B | 18.98 |
| Female Health (VERU) | United States | $0.084B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.070B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.063B | 17.33 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.062B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Neurotrope (NTRP) | United States | $0.034B | 0.00 |
| Senestech (SNES) | United States | $0.021B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.013B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.013B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.011B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 13.57 |
